title: Respiratory syncytial virus: how, why and what to do.
abstract: Bronchiolitis is the leading cause of hospitalization of infants and young children worldwide. Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis in infants. Studies conducted using molecular diagnostic assays confirmed that RSV accounts for over 50% of bronchiolitis in young children requiring hospitalization. Those studies demonstrate that it is common to identify RSV in association with a second viral agent but it is yet unclear whether the simultaneous detection of two or even three viruses is associated with increased disease severity. Despite extensive efforts, a vaccine for prevention of RSV infection is not yet available. Palivizumab a humanized monoclonal antibody directed against the F protein of RSV is the only agent licensed to prevent severe RSV disease in high-risk children. Among the new antivirals being developed for treatment of RSV infections, an RNA-interference based agent has demonstrated promising results for treatment of lung transplant recipients with acute RSV infection.
authors.affiliation: Hospital Materno-Infantil Gregorio Marañón, Madrid, Spain.
authors.forename: Rosa
authors.initials: R
authors.lastname: Rodriguez
authors.forename: Octavio
authors.initials: O
authors.lastname: Ramilo
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage*; D001988:Bronchiolitis / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control*; D018890:Chemoprevention / Q000379:methods; D002675:Child, Preschool; D060085:Coinfection / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D007223:Infant; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control* / Q000821:virology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab
keywords: Bronchiolitis; Palivizumab; RNAi; Respiratory Syncytial Virus, RSV; Viral coinfections